Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A global, randomized registration-enabling Phase 3 trial of avapritinib and sunitinib in patients with PDGFRA- and KIT-driven second-line advanced GIST who do not have the KIT V654A or T670I mutations

Next Previous
Trial Profile

A global, randomized registration-enabling Phase 3 trial of avapritinib and sunitinib in patients with PDGFRA- and KIT-driven second-line advanced GIST who do not have the KIT V654A or T670I mutations

Planning
Phase of Trial: Phase III

Latest Information Update: 02 Dec 2018

At a glance

  • Drugs Avapritinib (Primary) ; Sunitinib (Primary)
  • Indications Gastrointestinal stromal tumours
  • Focus Registrational; Therapeutic Use
  • Acronyms COMPASS-2L
  • Sponsors Blueprint Medicines

    • Most Recent Events

    • 02 Dec 2018 New trial record
    • 15 Nov 2018 According to a media release, the company plans to initiate the trial in the second half of 2019
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top